[Group News]

China Regenerative Medicine International Limited
(Stock Code: 8158.HK)

CRMI Attends the 11^th Medical Fair Asia in Singapore
Accelerates Entering the Southeast Asia Market

(5 September, 2016 - Hong Kong) - China Regenerative Medicine International Limited ("CRMI" or the "Company," stock code: 8158.HK, together with its subsidiaries, collectively the "Group") attended the 11^th Medical Fair Asia in Singapore (the "Trade Fair"). The Group's products were presented at the Trade Fair to further explore the Southeast Asia and overseas markets.

As Southeast Asia's leading showcase for innovative medical technology, equipment and devices, the Medical Fair Asia is organized by Messe Düsseldorf ASIA every two years. Around over 5000 exhibitors and buyers from South East Asia have participated in this Trade Fair.

Since October 2015, the Group has entered into a distributor agreement with the Philippines and initiated overseas marketing, "Acornea", as a world-leading, pioneering bio-engineered cornea, became the Group's key product in the development of overseas markets. Recently, "Acornea" has entered the European market. Besides, "Acornea" was listed as one of the "five key science Revolutions in China" by BBC, and also covered by CBS News. As a result, Acornea has been gradually drawing attentions from the international society. In Southeast Asia countries however,
there is only very limited numbers of human donated corneas due to their religious belief, which created an enormous market for "Acornea" to concentrate as its significant market.

In addition, the other three top biomedical products presented on the fair, "Gegreen", calcined bovine bone, "Asiunin", acellular anal fistula repair stroma, and "3DFlo(R) cell culture system", three-dimensional cell infusion type training, have brought surprises and grabbed the eyes among the peers in the industry.

The Trade Fair allows CRMI to quickly explore more reliable overseas partners, as well as to enhance the awareness of the Group's products and technologies within the industry, to cultivate and develop overseas target markets. Meanwhile, the Group will continue to attract investments worldwide and cooperate with other professional marketing teams to jointly contribute to the industry development. Overseas development email: marketing-oversea@crmi.cn

-End-
About CRMI (8158.HK)
China Regenerative Medicine International Limited ("CRMI"), listed on The Stock Exchange of Hong Kong Limited on 18 July 2001 (Stock Code: 8158.HK), is a leading enterprise in tissue engineering and regenerative medicine field. CRMI has obtained more than 70 independent intellectual property rights and undertaken various national pivotal projects including the "863 High-Tech Program," and the "973 High-Tech Program," etc. The Company has presided over the development of the industry standards on two occasions, and also received many awards including the First Class Award of the National Science and Technology Award. In 2014, CRMI collaborated with the University of Oxford in the UK to establish the "CRMI Technology Centre at the University of Oxford," which became the core R&D hub of the Company. On 21 October 2015, CRMI, as the only tissue engineering company that visited the UK along with Chinese President Xi Jinping, entered into a memorandum of understanding (the "MOU") with CCB International (Holdings) Limited ("CCBI", a wholly-owned subsidiary of China Construction Bank Corporation) and the Chancellor, Masters and Scholars of the University of Oxford (the "University of Oxford") regarding the joint establishment of strategic platform for industrialisation of biomedical research. This is also one of the 28 cooperation achievements introduced during the State Visit to the United Kingdom by President Xi.

CRMI has classified its business into three segments, i.e. tissue engineering,
biotechnology as well as cosmetics. Among which, "ActivSkin" , the only tissue-engineered skin with living cells that was approved by CFDA in China; "Acornea", the world's first tissue engineered cornea in the market that has completed all the necessary clinical trials and obtained its product certificate approved by the China Food and Drug Administration; "Gegreen", the Calcined Bovine Bone; Asiunin ,the Acellular Anal Fistula Repair Stroma; CS-ACI, the Cell Sheet-Autologous Chondrocyte Implantation; "Megreen"; Biological Membrane for guided Tissue Regeneration. Utilizing growth factors from the production of tissue engineering, the group launched bio-medical active cosmetics - "AMYbio", and collaborated with Mila D'Opiz Group in Switzerland to jointly develop the renowned Swiss skincare brand "Ascara".

About "Acornea"

The tissue engineered cornea product "Acornea", developed by CRMI after over ten years of research effort, with ownership of the intellectual property rights, is a state-of-art breakthrough in the field of applied Regenerative Medicine. Clinical trial data shows an overall transplantation efficacy of 94.44%, with recovery rates very similar to that of human donated corneas. We received Acornea's product certificate issued by CFDA on 28 April 2015. As the world's first tissue engineered cornea that has completed all the necessary clinical trials and obtained its product certificate. The commercial production and sale of this product commenced in 23 May 2015.

- Awarded as one of the "2015 China Top Ten Advances in Pharmaceutical Biotechnology"

- Awarded by Chinese Medical Association Ophthalmology Branch as "2015 China top ten ophthalmic achievements."

- Awarded by China Hi-Tech Fair as "Outstanding Product";

- Awarded by BBC as ""one of China's five major scientific and technological revolutionS"

About "Gegreen"

Gegreen is the first dental implant material developed in China. The product is produced through low temperature calcination and is used to promote bone regeneration after dental surgeries. Major clinical applications of Gegreen include treatment of periodontitis and other periodontal bone defects. Gegreen provides an excellent alternative to other dental implant materials such as Bio-Oss.

About "Asiunin"

Asiunin (Acellular Anal Fistula Repair Stroma) received production registration certificate from CFDA on October 2015 for treating anal fistula. The product utilizes the natural structure of stroma as 3D scaffold, which facilities the repair of anal sphincter tissue. Compare with routine treatment method of anal fistula, application of Asiunin reduces damage to anal sphincter tissue, promotes tissue repair, and shortens hospital stay. It is a significant improvement in the treatment of anal fistula.

About "3DFlo(R) Cell Culture System"

The 3DFlo(R) cell culture system aims to provide a state-of-art perfusion cell culture system for research institutions and pharmaceutical companies. 3DFlo(R) is capable to achieve continuous cell culture, control of cell differentiation, and real-time monitoring of culture environment. Through combination with different biomaterials and scaffolds, 3DFlo(R) mimics a more in vivo-like cell culturing environment, which allows more precise and reliable detection of drug cytotoxicity. As a result, 3DFlo(R) can reduce late stage clinical trials failures by first identifying unsafe drugs and through selection of the most efficacious candidates earlier in the drug development process.